$NTRA

Brophy Michael Burkes sold $216K of NTRA

Brophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 795 shares of Natera, Inc. (NTRA) at an average of $271.74 ($267.99–$274.22, $0.22M total) across 2 trades over 2026-08-03 to 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brophy Michael Burkes
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed open-market sale reduces the insider’s direct holdings but does not, by itself, imply new information about Natera’s near-term fundamentals.

02

Market read

Traders may briefly watch for sentiment effects from insider selling, but the 10b5-1 framing lowers the signal strength.

03

What to watch

The article does not state whether other insiders sold/bought around the same window, nor does it provide total insider ownership changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed Aug 5, covering sales executed Aug 3 to Aug 4

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc., reported by the CFO.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CFO Brophy Michael Burkes sold about $216K of NTRA shares via a 10b5-1 plan on Aug 3 to Aug 4.

Expected impact

Likely limited near-term impact; any effect would be short-lived unless paired with other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with stated 10b5-1 pre-arrangement, and the article provides no accompanying earnings, guidance, or operational developments.

Market effects

Minimal; insider sales under 10b5-1 typically do not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose CFO insider sale is disclosed in the Form 4.

  • Brophy Michael Burkes

    Natera CFO who executed the reported open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.